본문으로 건너뛰기
← 뒤로

IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer.

Internal medicine (Tokyo, Japan) 2026

Watanabe N, Yoshida S, Osano K, Ohkoshi K, Ishii T, Konishi M, Nakada H, Ashizawa N, Nakayama Y, Mitsui H, Takahashi K, Nakashima A

📝 환자 설명용 한 줄

An elderly woman undergoing trastuzumab emtansine (T-DM1) treatment for HER2-positive breast cancer visited our department with purpura, hematuria, proteinuria, and a decreased renal function.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Watanabe N, Yoshida S, et al. (2026). IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer.. Internal medicine (Tokyo, Japan). https://doi.org/10.2169/internalmedicine.6751-25
MLA Watanabe N, et al.. "IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer.." Internal medicine (Tokyo, Japan), 2026.
PMID 41780977

Abstract

An elderly woman undergoing trastuzumab emtansine (T-DM1) treatment for HER2-positive breast cancer visited our department with purpura, hematuria, proteinuria, and a decreased renal function. A skin biopsy revealed leukocytoclastic vasculitis with immunoglobulin A (IgA) deposition, confirming the diagnosis of IgA vasculitis. Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. A renal biopsy performed five months post-treatment revealed persistent mild proliferative glomerulonephritis with fibrotic crescent formation. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.

같은 제1저자의 인용 많은 논문 (1)